Fox Hill Wealth Management Has $1.31 Million Stock Position in DaVita Inc. (NYSE:DVA)

Key Points

• Fox Hill Wealth Management reduced its stake in DaVita Inc. by 44.3% in the first quarter, now holding 8,536 shares valued at $1,306,000.
• DaVita reported an earnings per share of $2.95 for the latest quarter, surpassing analysts' expectations of $2.70 and displaying a 6.1% increase in revenue year-over-year.
• Institutional investors now own 90.12% of DaVita's stock, with significant recent investments from Epoch Investment Partners and Iron Triangle Partners.

Fox Hill Wealth Management lessened its stake in DaVita Inc. (NYSE:DVA - Free Report) by 44.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,536 shares of the company's stock after selling 6,800 shares during the quarter. Fox Hill Wealth Management's holdings in DaVita were worth $1,306,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its holdings in shares of DaVita by 73.0% during the 1st quarter. Russell Investments Group Ltd. now owns 56,248 shares of the company's stock valued at $8,529,000 after acquiring an additional 23,736 shares in the last quarter. Resona Asset Management Co. Ltd. increased its stake in DaVita by 1.3% during the 1st quarter. Resona Asset Management Co. Ltd. now owns 14,485 shares of the company's stock worth $2,210,000 after buying an additional 183 shares during the period. HighTower Advisors LLC increased its stake in DaVita by 1.8% during the 1st quarter. HighTower Advisors LLC now owns 16,333 shares of the company's stock worth $2,498,000 after buying an additional 296 shares during the period. Public Sector Pension Investment Board increased its stake in DaVita by 4.9% during the 1st quarter. Public Sector Pension Investment Board now owns 5,841 shares of the company's stock worth $893,000 after buying an additional 274 shares during the period. Finally, CCM Investment Group LLC purchased a new stake in DaVita during the 1st quarter worth $704,000. Institutional investors and hedge funds own 90.12% of the company's stock.

Insider Activity at DaVita

In related news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at $3,905,700. The trade was a 8.28% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by insiders.

DaVita Stock Performance

DaVita stock traded up $0.96 during midday trading on Friday, reaching $135.35. 721,001 shares of the stock traded hands, compared to its average volume of 868,112. The company has a current ratio of 1.39, a quick ratio of 1.34 and a debt-to-equity ratio of 23.18. The firm has a fifty day moving average price of $139.74 and a two-hundred day moving average price of $145.73. The firm has a market cap of $9.68 billion, a price-to-earnings ratio of 13.31, a PEG ratio of 0.96 and a beta of 1.09. DaVita Inc. has a fifty-two week low of $126.07 and a fifty-two week high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping analysts' consensus estimates of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The business had revenue of $3.38 billion for the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the previous year, the firm earned $2.00 EPS. The business's revenue for the quarter was up 6.1% on a year-over-year basis. On average, equities research analysts forecast that DaVita Inc. will post 10.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Wall Street Zen raised shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Barclays dropped their target price on shares of DaVita from $169.00 to $160.00 and set an "equal weight" rating for the company in a research report on Thursday, August 7th. Finally, Truist Financial set a $148.00 target price on shares of DaVita in a research report on Friday, August 8th.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.